BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 20068276)

  • 1. [Comparison of micafungin and fosfluconazole as prophylaxis for invasive fungal infection during neutropenia in children undergoing chemotherapy and hematopoietic stem cell transplantation].
    Sawada A; Sakata N; Higuchi B; Takeshita Y; Ishihara T; Sakata A; Kouroki M; Kondo O; Koyama M; Hirano S; Yasui M; Inoue M; Yoshioka A; Kawa K
    Rinsho Ketsueki; 2009 Dec; 50(12):1692-9. PubMed ID: 20068276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.
    van Burik JA; Ratanatharathorn V; Stepan DE; Miller CB; Lipton JH; Vesole DH; Bunin N; Wall DA; Hiemenz JW; Satoi Y; Lee JM; Walsh TJ;
    Clin Infect Dis; 2004 Nov; 39(10):1407-16. PubMed ID: 15546073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation.
    Hashino S; Morita L; Takahata M; Onozawa M; Nakagawa M; Kawamura T; Fujisawa F; Kahata K; Izumiyama K; Yonezumi M; Chiba K; Kondo T; Asaka M
    Int J Hematol; 2008 Jan; 87(1):91-7. PubMed ID: 18224421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation.
    Hiramatsu Y; Maeda Y; Fujii N; Saito T; Nawa Y; Hara M; Yano T; Asakura S; Sunami K; Tabayashi T; Miyata A; Matsuoka KI; Shinagawa K; Ikeda K; Matsuo K; Tanimoto M;
    Int J Hematol; 2008 Dec; 88(5):588-595. PubMed ID: 19039629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.
    Yoshikawa K; Nakazawa Y; Katsuyama Y; Hirabayashi K; Saito S; Shigemura T; Tanaka M; Yanagisawa R; Sakashita K; Koike K
    Infection; 2014 Aug; 42(4):639-47. PubMed ID: 24567233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of micafungin for febrile neutropenia in pediatric patients with hematological malignancies: a multicenter prospective study.
    Kobayashi R; Suzuki N; Yoshida M; Iizuka S; Suzuki D; Sano H; Kudoh T
    J Pediatr Hematol Oncol; 2013 Oct; 35(7):e276-9. PubMed ID: 23743960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different doses of micafungin for prophylaxis of invasive fungal diseases in hemato-oncological high-risk patients: a web-based non-interventional trial in four large university hospitals in Germany.
    Heimann SM; Vehreschild MJ; Meintker L; Heinz W; Schroeder T; von Bergwelt-Baildon M; Cornely OA; Vehreschild JJ
    Transpl Infect Dis; 2014 Dec; 16(6):968-74. PubMed ID: 25371351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients.
    Park S; Kim K; Jang JH; Kim SJ; Kim WS; Chung DR; Kang CI; Peck KR; Jung CW
    J Infect; 2016 Nov; 73(5):496-505. PubMed ID: 27394404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation.
    Schonfeld W; Wang Cheng J; Tong KB; Seifeldin R
    Clin Ther; 2008 May; 30(5):964-73. PubMed ID: 18555943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
    Sohn HS; Lee TJ; Kim J; Kim D
    Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of recurrent candidemia due to candidal thrombophlebitis associated with a central venous catheter using a combination of fosfluconazole and micafungin.
    Hagiya H; Kajioka H
    Intern Med; 2013; 52(18):2139-43. PubMed ID: 24042529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal prophylaxis with micafungin in patients treated for childhood cancer.
    Kusuki S; Hashii Y; Yoshida H; Takizawa S; Sato E; Tokimasa S; Ohta H; Ozono K
    Pediatr Blood Cancer; 2009 Oct; 53(4):605-9. PubMed ID: 19533659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients.
    Vehreschild MJ; von Bergwelt-Baildon M; Tran L; Shimabukuro-Vornhagen A; Wisplinghoff H; Bangard C; Cornely OA; Vehreschild JJ
    Eur J Haematol; 2014 Nov; 93(5):400-6. PubMed ID: 24798021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
    Ziakas PD; Kourbeti IS; Mylonakis E
    Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Is micafungin useful in the prophylaxis of invasive fungal disease in hematological patients?].
    Salavert M; Jarque I
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():43-9. PubMed ID: 21420577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of micafungin versus extensive azoles in the prevention and treatment of invasive fungal infections for neutropenia patients with hematological malignancies: A meta-analysis of randomized controlled trials.
    Lee CH; Lin JC; Ho CL; Sun M; Yen WT; Lin C
    PLoS One; 2017; 12(7):e0180050. PubMed ID: 28700646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant.
    Huang X; Chen H; Han M; Zou P; Wu D; Lai Y; Huang H; Chen X; Liu T; Zhu H; Wang J; Hu J
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1509-16. PubMed ID: 22469884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Why might micafungin be the drug of choice in pediatric patients?].
    Ramos Amador JT; Prieto Tato L; Guillén Martín S
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():23-8. PubMed ID: 21420573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.
    Mehta PA; Vinks AA; Filipovich A; Bleesing J; Jodele S; Jordan MB; Marsh R; Tarin R; Edwards S; Fearing D; Lawrence J; Davies SM
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1458-62. PubMed ID: 20546908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal prophylaxis with micafungin in neutropenic patients with hematological malignancies.
    Hirata Y; Yokote T; Kobayashi K; Nakayama S; Oka S; Miyoshi T; Akioka T; Hiraoka N; Iwaki K; Takayama A; Nishimura Y; Makino J; Takubo T; Tsuji M; Hanafusa T
    Leuk Lymphoma; 2010 May; 51(5):853-9. PubMed ID: 20214445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.